Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dual Incontinence Clear all
Active, not recruiting Not applicable Interventional

Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery

NCT03522961
View directory record Official record
Conditions
Urinary Tract Infections, Pelvic Organ Prolapse, Urinary Incontinence
Interventions
Nitrofurantoin Prophylaxis/Placebo, Cranberry capsules
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 22, 2026, 2:36 PM EDT
Completed No phase listed Observational

Bladder Antimuscarinic Medication and Accidental Bowel Leakage

NCT03543566
View directory record Official record
Conditions
Urinary Incontinence, Urge, Fecal Incontinence
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

NCT05702827
View directory record Official record
Conditions
Stress Urinary Incontinence, Surgical Incision, Pain Vulva
Interventions
Bupivacaine-Meloxicam
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 22, 2026, 2:36 PM EDT
Not listed Not applicable Interventional

Urinary Stress Incontinence and Urgency in Women With EMSELLA

NCT03877640
View directory record Official record
Conditions
Stress Urinary Incontinence, Urge Incontinence
Interventions
BTL EMSELLA
Device
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 22, 2026, 2:36 PM EDT
Terminated Not applicable Interventional Results available

Sacral Neuromodulation in Dual Incontinence: Ultrasound and Afferent Nerve Sensation Assessment

NCT02357784
View directory record Official record
Conditions
Dual Incontinence, Fecal Incontinence, Urinary Incontinence, Sacral Neuromodulation
Interventions
Neurometer
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 22, 2026, 2:36 PM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Jul 22, 2026, 2:36 PM EDT
Active, not recruiting Phase 3 Interventional

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

NCT03104517
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
AMDC-USR (iltamiocel), Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 4 Interventional

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

NCT00147654
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
95
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 22, 2026, 2:36 PM EDT
Not listed Phase 2Phase 3 Interventional

This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

NCT00479596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox
Drug
Lead sponsor
Urological Sciences Research Foundation
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced Jul 22, 2026, 2:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Nitrofurantoin and Urinary Tract Infections (UTIs)

NCT00678041
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Nitrofurantoin, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jul 22, 2026, 2:36 PM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 9, 2010 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence

NCT03397771
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Litoxetine, placebo
Drug
Lead sponsor
Ixaltis SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
82
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
75
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

NCT03052764
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence
Interventions
onabotulinumtoxinA, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Laguna Hills, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

NCT03320850
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder With Urinary Incontinence
Interventions
OnabotulinumtoxinA and Hydrogel admixture, Placebo and Hydrogel admixture
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

NCT03241342
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
GTx 024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
62
States / cities
Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

NCT01371994
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Autologous Muscle Derived Cells for Female Urinary Sphincter Repair

NCT01893138
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Placebo, Iltamiocel
Other · Biological
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Agoura Hills, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence

NCT00345332
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Botox, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
3
States / cities
Sacramento, California • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

NCT00196404
View directory record Official record
Conditions
Urinary Incontinence
Interventions
DR-3001a, DR-3001b, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Jul 22, 2026, 2:36 PM EDT
Completed Phase 4 Interventional Results available

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

NCT01018264
View directory record Official record
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
solifenacin succinate (VESIcare), placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 22, 2026, 2:36 PM EDT